MiR-186 achieved the regulation of cisplatin sensitivity on ovarian cancer cells in two directions simultaneously, which not only inhibiting PIK3R3 and PTEN, but also promoting expression of APAF1 as well (12). This evidence concerns the gene PTEN and ovarian cancer.